Read on Twitter
Some great abstracts in #mesothelioma @AACR2023.
1) Response to CART #meso associated with density of infiltrative TILs with PDL1 and TIGIT as potential targets of resistance. Explains what we see with better outcomes for CART-meso followed by anti-PD1? aacrjournals.org/cancerres/arti…
1) Response to CART #meso associated with density of infiltrative TILs with PDL1 and TIGIT as potential targets of resistance. Explains what we see with better outcomes for CART-meso followed by anti-PD1? aacrjournals.org/cancerres/arti…
2) Data on TEAD inhibitors in #meso. No MTD reached. Response does not correlate with NF2 mutation status. Will need to confirm with larger n. @IbiayiMD @curemeso
aacrjournals.org/cancerres/arti…
aacrjournals.org/cancerres/arti…
3) Building on observation 👆that PD1 May be resistance mech to CARTmeso.
BZDS1901 adds PD1 nanobody. 11 MPM pts: 1 CR, 6 PR, 4 SD. Longest PFS 26 mo. @curemeso
aacrjournals.org/cancerres/arti…
BZDS1901 adds PD1 nanobody. 11 MPM pts: 1 CR, 6 PR, 4 SD. Longest PFS 26 mo. @curemeso
aacrjournals.org/cancerres/arti…
4) ATOMIC-meso looking at ADI-PEG20 in non-epi #meso.
Better ⭐️PFS and ⭐️ OS with chemo vs chemo alone. Given poor outcomes with chemo in this population. This is a welcome addition. @perth_meso_dr @curemeso @dean_fennell
aacrjournals.org/cancerres/arti…
Better ⭐️PFS and ⭐️ OS with chemo vs chemo alone. Given poor outcomes with chemo in this population. This is a welcome addition. @perth_meso_dr @curemeso @dean_fennell
aacrjournals.org/cancerres/arti…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
